Literature DB >> 33708215

Natural Killer Anti-Tumor Activity Can Be Achieved by In Vitro Incubation With Heat-Killed BCG.

Gloria Esteso1, Nacho Aguiló2, Esther Julián3, Omodele Ashiru4, Mei M Ho4, Carlos Martín2, Mar Valés-Gómez1.   

Abstract

Natural Killer cell receptors allow this heterogeneous immune population to efficiently fight both tumors and infection, so their use as immunotherapy agents is an active field of research. Cytokine activation, particularly by myeloid cell-derived IL15, can induce potent NK anti-tumor responses. While studying the mechanism of action of intravesical instillations of Bacille Calmette-Guérin (BCG) as therapy for patients with high risk non-muscle invasive bladder cancer, we showed that BCG can activate a cytotoxic CD56bright NK cell population which efficiently recognized bladder cancer cells. This pioneer immunotherapy provides an invaluable model to understand the role of different immune populations in tumor elimination. However, during the propagation of BCG worldwide a large number of genetically diverse BCG substrains developed. Here, we investigated the capacity of different BCG substrains to promote NK cell activation and confirmed that they were able to activate lymphocytes. Tice, Connaught and Moreau were the substrains with a stronger NK activation effect as measured by CD56 upregulation. Surprisingly, dead mycobacteria also stimulated PBMC cultures and we further demonstrate here that subcellular fractions of BCG-Tice, in the absence of live mycobacteria, could also induce an NK cell response. Lipids from BCG-Tice, but not from Mycobacterium bovis, stimulated NK cell activation and degranulation, whereas the aqueous fraction of either bacteria did not activate lymphocytes. However, delipidated BCG-Tice bacteria were able to activate effector cells (CD3+CD56+ and NK, CD3-CD56+). These data demonstrate that different components of mycobacteria can stimulate different immune subpopulations resulting in phenotypes suitable for cancer elimination.
Copyright © 2021 Esteso, Aguiló, Julián, Ashiru, Ho, Martín and Valés-Gómez.

Entities:  

Keywords:  BCG strains; CD56bright; NK activation; bladder cancer; cancer immunology; mycobacterial fractions

Year:  2021        PMID: 33708215      PMCID: PMC7940681          DOI: 10.3389/fimmu.2021.622995

Source DB:  PubMed          Journal:  Front Immunol        ISSN: 1664-3224            Impact factor:   7.561


  35 in total

1.  Report of an International collaborative study to establish the first WHO reference reagents for BCG vaccines of three different sub-strains.

Authors:  Mei M Ho; Kevin Markey; Peter Rigsby; Jason Hockley; Michael J Corbel
Journal:  Vaccine       Date:  2010-11-04       Impact factor: 3.641

2.  Mapping the global use of different BCG vaccine strains.

Authors:  Nicole Ritz; Nigel Curtis
Journal:  Tuberculosis (Edinb)       Date:  2009-06-18       Impact factor: 3.131

3.  Characterization of a human anti-tumoral NK cell population expanded after BCG treatment of leukocytes.

Authors:  Eva M García-Cuesta; Gloria Esteso; Omodele Ashiru; Sheila López-Cobo; Mario Álvarez-Maestro; Ana Linares; Mei M Ho; Luis Martínez-Piñeiro; Hugh T Reyburn; Mar Valés-Gómez
Journal:  Oncoimmunology       Date:  2017-02-21       Impact factor: 8.110

4.  Loss of RD1 contributed to the attenuation of the live tuberculosis vaccines Mycobacterium bovis BCG and Mycobacterium microti.

Authors:  Alexander S Pym; Priscille Brodin; Roland Brosch; Michel Huerre; Stewart T Cole
Journal:  Mol Microbiol       Date:  2002-11       Impact factor: 3.501

5.  Genome plasticity of BCG and impact on vaccine efficacy.

Authors:  Roland Brosch; Stephen V Gordon; Thierry Garnier; Karin Eiglmeier; Wafa Frigui; Philippe Valenti; Sandrine Dos Santos; Stéphanie Duthoy; Céline Lacroix; Carmen Garcia-Pelayo; Jacqueline K Inwald; Paul Golby; Javier Nuñez Garcia; R Glyn Hewinson; Marcel A Behr; Michael A Quail; Carol Churcher; Bart G Barrell; Julian Parkhill; Stewart T Cole
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-19       Impact factor: 11.205

6.  A historical and molecular phylogeny of BCG strains.

Authors:  M A Behr; P M Small
Journal:  Vaccine       Date:  1999-02-26       Impact factor: 3.641

7.  Nonspecific immunotherapy with BCG vaccine in bladder tumors: a preliminary report.

Authors:  J A Martinez-Piñeiro; P Muntañola
Journal:  Eur Urol       Date:  1977       Impact factor: 20.096

Review 8.  The role of mycobacterial cell wall nucleic acid complex in the treatment of bacillus Calmette-Guérin failures for non-muscle-invasive bladder cancer.

Authors:  Vignesh T Packiam; Shane M Pearce; Gary D Steinberg
Journal:  Ther Adv Urol       Date:  2016-02

Review 9.  NK-92: an 'off-the-shelf therapeutic' for adoptive natural killer cell-based cancer immunotherapy.

Authors:  Garnet Suck; Marcus Odendahl; Paulina Nowakowska; Christian Seidl; Winfried S Wels; Hans G Klingemann; Torsten Tonn
Journal:  Cancer Immunol Immunother       Date:  2015-11-11       Impact factor: 6.968

10.  Functional analysis of human NK cells by flow cytometry.

Authors:  Yenan T Bryceson; Cyril Fauriat; João M Nunes; Stephanie M Wood; Niklas K Björkström; Eric O Long; Hans-Gustaf Ljunggren
Journal:  Methods Mol Biol       Date:  2010
View more
  2 in total

1.  Impact of an Immune Modulator Mycobacterium-w on Adaptive Natural Killer Cells and Protection Against COVID-19.

Authors:  Sarita Rani Jaiswal; Jaganath Arunachalam; Ashraf Saifullah; Rohit Lakhchaura; Dhanir Tailor; Anupama Mehta; Gitali Bhagawati; Hemamalini Aiyer; Bakulesh Khamar; Sanjay V Malhotra; Suparno Chakrabarti
Journal:  Front Immunol       Date:  2022-05-04       Impact factor: 8.786

Review 2.  Effects of Mycobacterium bovis Calmette et Guérin (BCG) in oncotherapy: Bladder cancer and beyond.

Authors:  Neelam Mukherjee; Esther Julián; Jordi B Torrelles; Robert S Svatek
Journal:  Vaccine       Date:  2021-10-07       Impact factor: 4.169

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.